Companies › Takeda
35 active drug programs in 164 registered trials: 77 Phase 2, 50 Phase 3, 21 Phase 4, 16 Phase 1; Oncology, Immunology, Hematology, Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vedolizumab Integrin alpha-4/beta-7 inhibitor | ITGA4, ITGB7 | Phase 4 | Ulcerative Colitis; Crohn's Disease; Crohn's Disease (CD); Moderately to Severely Active Ulcerative Colitis … | May 2027 |
| Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 4 | Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus … | Jul 2027 |
| Fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 4 | Colorectal Cancer | Oct 2027 |
| Replagal alpha-galactosidase A (agalsidase alfa) enzyme replacement therapy | GLA | Phase 4 | Fabry Disease | Oct 2027 |
| Brentuximab Vedotin Tubulin inhibitor; Tumor necrosis factor receptor superfamily member 8 binding agent | Tubulin, TNFRSF8 | Phase 4 | Hodgkin Lymphoma; Lymphoma; Hodgkin Disease; Ann Arbor Stage III Hodgkin Lymphoma … | Dec 2027 |
| TAK-861 Histamine H3 receptor antagonist | – | Phase 3 | Narcolepsy Type 1 (NT1); Narcolepsy Type 1 | Dec 2026 |
| Tetravalent Dengue Vaccine (TDV), new formulation (TAK-003) Live attenuated tetravalent dengue virus vaccine | – | Phase 3 | Dengue Fever | Dec 2026 |
| Maribavir Serine/threonine-protein kinase BGLF4 inhibitor; Phosphotransferase pUL97 inhibitor | UL97 | Phase 3 | Cytomegalovirus (CMV); Hematologic Malignancy | Jan 2027 |
| Zasocitinib TEC kinase inhibitor | TEC, ZAP70 | Phase 3 | Psoriatic Arthritis; Plaque Psoriasis; Hidradenitis Suppurativa; Nonsegmental Vitiligo … | Feb 2027 |
| Teduglutide Glucagon-like peptide 2 receptor agonist | GLP2R | Phase 3 | Short Bowel Syndrome | Feb 2027 |
| TAK-279 | – | Phase 3 | Plaque Psoriasis; Crohn's Disease; Ulcerative Colitis | Feb 2027 |
| Apadamtase Alfa (TAK-755) A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein | ADAMTS13 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP); Acute Ischemic Stroke | Mar 2027 |
| Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL); Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive … | Jul 2027 |
| Vonicog Alfa von Willebrand factor exogenous protein | VWF | Phase 3 | Von Willebrand Disease (VWD) | Nov 2027 |
| Elritercept Erythropoietin receptor agonist | EPOR | Phase 3 | Myelodysplastic Syndromes; Myelodysplastic Syndrome; Myelofibrosis | Feb 2028 |
| Mezagitamab (TAK-079) Lymphocyte differentiation antigen CD38 binding agent | CD38 | Phase 3 | Immune Thrombocytopenic Purpura (ITP); Kidney Disease; Antibody-Mediated Rejection (AMR) | Mar 2028 |
| TAK-881 Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (r | – | Phase 3 | Primary Immunodeficiency Diseases (PID); Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | May 2028 |
| Fazirsiran Z-AAT reducing agent; inhibits expression of Z-AAT protein | SERPINA1 | Phase 3 | Alpha1-Antitrypsin Deficiency | Aug 2028 |
| TAK-330 Factor Xa inhibitor reversal agent (recombinant human Factor Xa) | F10 | Phase 3 | Coagulation Disorder | Aug 2028 |
| IGI, 10% (Gammagard Liquid, TAK-339, KIOVIG) Immune globulin infusion (human), 10% IV | – | Phase 3 | Multiple Myeloma | Sep 2028 |
| TAK-928 | – | Phase 3 | IO Resistant Squamous and Nonsquamous NSCLC | Nov 2028 |
| Vortioxetine Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist | HTR1A, SLC6A4, HTR3A | Phase 3 | Major Depressive Disorder; Glioblastoma; Depression | Sep 2029 |
| TDV (QDENGA, TAK-003) Tetravalent live attenuated dengue virus vaccine | – | Phase 3 | Dengue Fever | Mar 2030 |
| Mobocertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung | – |
| TAK-360 Orexin receptor agonist | HCRT | Phase 2 | Idiopathic Hypersomnia; Narcolepsy Type 2; Narcolepsy Type 1 | Nov 2026 |
| Rusfertide Hepcidin mimetic | HAMP | Phase 2 | Polycythemia Vera | Oct 2027 |
| TAK-411 Hypersialylated Immune Globulin G with immunomodulatory properties | – | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Dec 2027 |
| TAK-226 Erythropoietin receptor agonist | EPOR | Phase 2 | Myelodysplastic Syndromes | Jun 2028 |
| Elaprase Iduronate-2-sulfatase (IDS) enzyme replacement therapy administered intravenously | IDS | Phase 2 | Hunter Syndrome | Jan 2029 |
| Idursulfase-IT Iduronate-2-sulfatase (IDS) enzyme replacement therapy administered intrathecally | IDS | Phase 2 | Hunter Syndrome | Jan 2029 |
| TAK-007 CAR-T cell therapy | – | Phase 2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Dec 2038 |
| Mirvetuximab Soravtansine (TAK-853) Folate receptor alpha binding agent; Tubulin inhibitor | FOLR1, Tubulin | Phase 1 | Ovarian Cancer | Mar 2027 |
| TAK-781 | – | Phase 1 | Healthy Volunteers | Apr 2028 |
| TAK-188 CCR8 antagonist targeting regulatory T cells (Tregs) | CCR8 | Phase 1 | Advanced or Metastatic Solid Tumors | Dec 2028 |
| TAK-505 | – | Phase 1 | Malignant Solid Tumors | Aug 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02758717 | Brentuximab Vedotin | Phase 2 | Ann Arbor Stage IB Hodgkin Lymphoma | Oncology | Aug 2019 |
| NCT03807778 | Mobocertinib | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Nov 2021 |
| NCT04925973 | Tofacitinib | Phase 2 | Ulcerative Colitis Acute | Immunology | Dec 2023 |
| NCT04496960 | Tofacitinib | Phase 1 | Sjogren's Syndrome | Immunology | Jan 2025 |
| NCT03976245 | Tofacitinib | Phase 4 | Rheumatoid Arthritis | Immunology | Mar 2025 |
| NCT06112665 | Tofacitinib | Phase 4 | Axial Spondyloarthritis | Immunology | Mar 2025 |
| NCT07044141 | Tofacitinib | Phase 1 | Vitiligo | Immunology | Sep 2025 |
| NCT05595447 | Brentuximab Vedotin | Phase 2 | Hodgkin Lymphoma | Oncology | Oct 2025 |
| NCT04743518 | Vedolizumab | Phase 4 | Ulcerative Colitis | Immunology | Dec 2025 |
| NCT02734771 | Brentuximab Vedotin | Phase 2 | Diffuse Large B-Cell Lymphoma | Oncology | Dec 2025 |
| NCT04743518 | Tofacitinib | Phase 4 | Ulcerative Colitis | Immunology | Dec 2025 |
| NCT05481619 | Vedolizumab | Phase 4 | Ulcerative Colitis | Immunology | Jan 2026 |
| NCT06317220 | Vedolizumab | Phase 2 | Collagenous Gastritis | Gastroenterology | Feb 2026 |
| NCT06756152 | Vedolizumab | Phase 2 | Biphenotypic Acute Leukemia | Oncology | Jul 2026 |
| NCT07554820 | Tofacitinib | Phase 4 | Rheumatoid Arthritis | Cardiovascular | Aug 2026 |
| NCT04129502 | Mobocertinib | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Oncology | Sep 2026 |
| NCT02716116 | Mobocertinib | Phase 1 | Carcinoma, Non-Small-Cell Lung | Oncology | Sep 2026 |
| NCT03819296 | Vedolizumab | Phase 1 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Oncology | Oct 2026 |
| NCT03517137 | Brentuximab Vedotin | Phase 2 | Advanced Hodgkin Lymphoma | Oncology | Nov 2026 |
| NCT06812078 | TAK-360 | Phase 2 | Idiopathic Hypersomnia | Neurology | Nov 2026 |
| NCT06952699 | TAK-360 | Phase 2 | Narcolepsy Type 2 | Neurology | Nov 2026 |
| NCT06207123 | Ponatinib | Phase 1 | Acute Leukemia | Oncology | Dec 2026 |
| NCT07363720 | TAK-861 | Phase 3 | Narcolepsy Type 1 (NT1) | Neurology | Dec 2026 |
| NCT07047521 | Tetravalent Dengue Vaccine (TDV), new formulation (TAK-003) | Phase 3 | Dengue Fever | Infectious disease | Dec 2026 |
| NCT06841705 | Vedolizumab | Phase 2 | Immune Checkpoint Inhibitor-Related Colitis | Immunology | Dec 2026 |
| NCT05180097 | Brentuximab Vedotin | Phase 2 | Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT05814640 | Vortioxetine | Phase 1 | Depression | Psychiatry | Dec 2026 |
| NCT07131813 | Tofacitinib | Phase 4 | Oral Lichen Planus | Gastroenterology | Jan 2027 |
| NCT05319353 | Maribavir | Phase 3 | Cytomegalovirus (CMV) | Infectious disease | Jan 2027 |
| NCT05357794 | Brentuximab Vedotin | Phase 2 | Mycosis Fungoides | Oncology | Jan 2027 |
| NCT03739814 | Ponatinib | Phase 2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Oncology | Feb 2027 |
| NCT07244263 | Zasocitinib | Phase 2 | Hidradenitis Suppurativa | Immunology | Feb 2027 |
| NCT06973304 | Teduglutide | Phase 3 | Short Bowel Syndrome | Gastroenterology | Feb 2027 |
| NCT03356054 | Brentuximab Vedotin | Phase 1 | DLBCL | Oncology | Feb 2027 |
| NCT06233461 | TAK-279 | Phase 2 | Crohn's Disease | Immunology | Feb 2027 |
| NCT03057795 | Brentuximab Vedotin | Phase 2 | Classic Hodgkin Lymphoma | Oncology | Feb 2027 |
| NCT03147612 | Ponatinib | Phase 2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Oncology | Feb 2027 |
| NCT04683003 | Apadamtase Alfa (TAK-755) | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP) | Immunology | Mar 2027 |
| NCT06390995 | Mirvetuximab Soravtansine (TAK-853) | Phase 1 | Ovarian Cancer | Oncology | Mar 2027 |
| NCT07108283 | Zasocitinib | Phase 2 | Nonsegmental Vitiligo | Immunology | Mar 2027 |
| NCT03907488 | Brentuximab Vedotin | Phase 3 | Ann Arbor Stage III Hodgkin Lymphoma | Oncology | Mar 2027 |
| NCT06475820 | Vedolizumab | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | Apr 2027 |
| NCT06579755 | Tetravalent Dengue Vaccine (TDV), new formulation (TAK-003) | Phase 3 | Dengue Fever | Infectious disease | Apr 2027 |
| NCT06377566 | Brentuximab Vedotin | Phase 2 | Hodgkin Lymphoma | Oncology | Apr 2027 |
| NCT07313072 | Tofacitinib | Phase 2 | Nail Psoriasis | Immunology | Apr 2027 |
| NCT03113500 | Brentuximab Vedotin | Phase 2 | Adult T-Cell Leukemia/Lymphoma | Oncology | Apr 2027 |
| NCT06581328 | Vedolizumab | Phase 4 | Ulcerative Colitis | Immunology | May 2027 |
| NCT06581328 | Vedolizumab | Phase 4 | Ulcerative Colitis | Immunology | May 2027 |
| NCT03007030 | Brentuximab Vedotin | Phase 2 | CD30-Positive Neoplastic Cells Present | Oncology | May 2027 |
| NCT06671496 | Zasocitinib | Phase 3 | Psoriatic Arthritis | Immunology | May 2027 |
| NCT06671483 | Zasocitinib | Phase 3 | Psoriatic Arthritis | Immunology | May 2027 |
| NCT03712202 | Brentuximab Vedotin | Phase 2 | Ann Arbor Stage I Hodgkin Lymphoma | Oncology | May 2027 |
| NCT05845723 | Tofacitinib | Phase 2 | Aneurysm | Cardiovascular | Jun 2027 |
| NCT06227910 | Vedolizumab | Phase 3 | Crohn's Disease | Immunology | Jun 2027 |
| NCT06698822 | Tofacitinib | Phase 2 | Cutaneous T-Cell Lymphoma | Oncology | Jun 2027 |
| NCT06045754 | Vedolizumab | Phase 4 | Crohn's Disease | Immunology | Jun 2027 |
| NCT01896999 | Brentuximab Vedotin | Phase 1 | Recurrent Classic Hodgkin Lymphoma | Oncology | Jun 2027 |
| NCT06498089 | Tofacitinib | Phase 4 | Takayasu Arteritis | Immunology | Jun 2027 |
| NCT03233347 | Brentuximab Vedotin | Phase 2 | Ann Arbor Stage I Hodgkin Lymphoma | Oncology | Jul 2027 |
| NCT06095128 | Vedolizumab | Phase 4 | Ulcerative Colitis | Immunology | Jul 2027 |
The 60 nearest readouts of 164 trials; the rest in the app.
Cash and short-term investments of 536.5bn JPY on 2025-03-31; operating cash flow positive
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Tubulin (2) IDS (2) EPOR (2) ADAMTS13 (1) CD38 (1) ITGA4 (1) ITGB7 (1) TNFRSF8 (1) JAK3 (1) JAK1 (1) JAK2 (1) TYK2 (1)
Roche Sichuan Kelun-Biotech Biopharmaceutical Pfizer GSK AbbVie RemeGen Fidia Farmaceutici Beijing Biostar Pharmaceuticals Urotronic Ambrx
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.